Stakeholders are being encouraged to weigh in on the European Chemicals Agency (ECHA) 60-day public consultation period related to a planned ban on per-and-polyfluoroalkyl (PFAS) substances, also known as forever chemicals.
The widely used substances are sometimes used in the production of pharmaceuticals, including being found in some active pharmaceutical ingredients (APIs), raw materials used for chemical synthesis, as well as in reagents and manufacturing equipment.
ECHA is accepting public comment from 26 March-25 May on a recent draft opinion by its Socio-Economic Analysis Committee (SEAC) about the feasibility, benefits and costs of proposed EU-wide Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) restrictions on PFAS..
As part of the process for getting a REACH restriction on a substance that harms human health or the environment, authorities in EU member countries explain the background and risks in a dossier, which is then reviewed by the SEAC and RAC. Both committees recommended a ban on PFAS across the EU, allowing for targeted derogations.
In its final opinion, published 10 March, the RAC noted the growing and highly persistent health risks of PFAS, including cancer and reproductive harm. It called for EU-wide regulatory action to protect people and the environment as well as risk management requirements if derogations for specific uses are allowed, including emissions monitoring and reporting of PFAS emissions from manufacturing and industrial sites.
The restrictions can also apply to packaging materials using fluoropolymers, or combination products such as pre-filled syringes.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) said that it was “deeply concerned” about the ECHA opinions in a 26 March statement. It will take time to find alternatives to PFAS and the pharma industry needs a time-unlimited derogation, in EFPIA’s view.
Reference:
Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.
Oleylamine is a long-chain (C18) primary fatty amine derived from natural fatty acids, typically sourced from vegetable oils. It is produced from oleic acid through conversion of the carboxylic acid group (–COOH) into an amine group (–NH₂). With its optimal balance of hydrophobic chain length and reactive amine functionality it serves as a versatile and dependable building block for high-performance formulations.
Sodium Hyaluronate is the sodium salt of hyaluronic acid, a naturally occurring glycosaminoglycan known for its exceptional ability to retain moisture, along with its viscoelastic and biocompatible properties, making it highly valuable across pharmaceutical, cosmetic, and biomedical applications.
Pyrazinamide is a first-line antitubercular drug used in combination therapy for the treatment of tuberculosis (TB). It is a synthetic pyrazine derivative and acts as a prodrug, which is converted into its active form (pyrazinoic acid) inside Mycobacterium tuberculosis.